undamentalytics Newsletter

Boyd Steven: insider trades

Director, 10% owner at 7 companies we cover. 30 open-market purchases and 7 sales not made under a pre-set plan, reported from August 16, 2017 to March 7, 2022.

Would copying Boyd Steven’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 2 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on May 15, 2019 into $1,995 by November 2, 2026, −19.5% a year. The copy held shares only 21% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $14,585, +5.2% a year (the S&P 500 held throughout made $29,608, +15.7% a year). Beta against the index was 0.56. Twelve months after each report, the average purchase was −86.0% against the S&P 500 (median −86.0%), and 0% beat it. Measured from the trade date, the insider’s own timing, the average was −82.9%. After their sales, the shares moved −80.6% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$10.0k$20.0k$30.0k 20192020202120222023202420252026 $29.6k$14.6k$2.0k
Copying Boyd StevenS&P 500, same days investedS&P 500, held throughout $10,000 copying Boyd Steven’s open-market purchases from May 15, 2019, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−19.5%
S&P 500, same days invested
+5.2% (held throughout +15.7%)
Time in shares
21%
Sharpe ratio (S&P 500)
−0.39 (0.70)
Biggest drop (S&P 500)
−84% (−34%)
Market sensitivity (beta)
0.56
Purchases copied
2

Trade by trade

Boyd Steven: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 2 −40.6% −40.6% 0% 2 — — Not enough years
Purchases, 6 months after the report 2 −54.8% −54.8% 0% 2 — — Not enough years
Purchases, 12 months after the report 2 −86.0% −86.0% 0% 2 — — Not enough years
Purchases, 12 months after the trade 2 −82.9% −82.9% 0% 2 — — Not enough years
Sales, 3 months after the report 1 −55.4% −55.4% 100% 1 — — Not enough years
Sales, 12 months after the report 1 −80.6% −80.6% 100% 1 — — Not enough years
Sales, 12 months after the trade 1 −79.8% −79.8% 100% 1 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Avalo Therapeutics, Inc. AVTX —220August 16, 2017March 7, 2022
Kiora Pharmaceuticals Inc KPRX —61May 11, 2018July 29, 2021
Aytu Biopharma, Inc AYTU —12December 23, 2019April 29, 2020
Achieve Life Sciences, Inc. ACHV —11June 13, 2019June 13, 2019
Filana Therapeutics, Inc. FLNA —01August 20, 2018August 20, 2018
Traws Pharma, Inc. TRAW —01September 25, 2019September 25, 2019
Vyome Holdings, Inc HIND —01June 22, 2021June 22, 2021

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
March 7, 2022March 3, 2022 AVTX Purchase $344,500 not yetnot yetnot yet
February 22, 2022February 17, 2022 AVTX Purchase $232,010 not yetnot yetnot yet
January 14, 2022January 12, 2022 AVTX Purchase $451,342 not yetnot yetnot yet
August 18, 2021August 16, 2021 AVTX Purchase $138,100 not yetnot yetnot yet
July 29, 2021July 27, 2021 KPRX Sale $14,544,847 not yetnot yetnot yet
June 22, 2021June 16, 2021 HIND Sale $14,230,402 −55.4%−80.6%−79.7%
January 8, 2021January 6, 2021 KPRX Purchase $8,007,658 −44.2%−110.7%−107.6%
November 25, 2020November 23, 2020 AVTX Purchase $236,869 not yetnot yetnot yet
September 9, 2020September 4, 2020 AVTX Purchase $220,000 not yetnot yetnot yet
April 29, 2020April 27, 2020 AYTU Sale $9,298,236 not yetnot yetnot yet
March 31, 2020March 27, 2020 AVTX Purchase $265,346 not yetnot yetnot yet
March 12, 2020March 10, 2020 AYTU Sale $31,200,123 not yetnot yetnot yet
February 5, 2020February 3, 2020 AVTX Purchase $5,000,002 not yetnot yetnot yet
December 23, 2019December 19, 2019 AYTU Purchase $67,750 not yetnot yetnot yet
October 1, 2019September 29, 2019 KPRX Purchase $1,893,613 not yetnot yetnot yet
September 25, 2019September 23, 2019 TRAW Sale $13,016 not yetnot yetnot yet
September 3, 2019August 29, 2019 AVTX Purchase $134,554 not yetnot yetnot yet
August 20, 2019August 16, 2019 AVTX Purchase $42,189 not yetnot yetnot yet
June 13, 2019June 11, 2019 ACHV Sale $837,467 not yetnot yetnot yet
June 13, 2019June 11, 2019 ACHV Purchase $48,689 not yetnot yetnot yet
June 5, 2019June 3, 2019 AVTX Purchase $72,150 not yetnot yetnot yet
May 14, 2019May 10, 2019 AVTX Purchase $99,312 −37.1%−61.2%−58.2%
March 29, 2019March 27, 2019 KPRX Purchase $175,216 not yetnot yetnot yet
January 11, 2019January 9, 2019 AVTX Purchase $54,363 not yetnot yetnot yet
January 8, 2019January 4, 2019 AVTX Purchase $93,990 not yetnot yetnot yet
December 31, 2018December 28, 2018 AVTX Purchase $121,791 not yetnot yetnot yet
December 12, 2018December 10, 2018 KPRX Purchase $40,213 not yetnot yetnot yet
December 4, 2018November 30, 2018 AVTX Purchase $90,070 not yetnot yetnot yet
November 16, 2018November 14, 2018 KPRX Purchase $161,028 not yetnot yetnot yet
October 29, 2018October 25, 2018 AVTX Purchase $425,456 not yetnot yetnot yet
August 20, 2018August 17, 2018 AVTX Purchase $3,910,000 not yetnot yetnot yet
August 20, 2018August 16, 2018 FLNA Sale $1,276,880 not yetnot yetnot yet
July 18, 2018July 16, 2018 AVTX Purchase $128,455 not yetnot yetnot yet
May 11, 2018May 9, 2018 KPRX Purchase $91,428 not yetnot yetnot yet
September 28, 2017September 26, 2017 AVTX Purchase $11,175 not yetnot yetnot yet
August 29, 2017August 25, 2017 AVTX Purchase $83,230 not yetnot yetnot yet
August 16, 2017August 14, 2017 AVTX Purchase $585,092 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Boyd Steven traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.